MADRIGAL PHARMACEUTICALS INC (MDGL)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for MDGL
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| MDGL | Class III Director | 68 | ["Executive Vice President and Chief Drug Development Officer at Incyte from January 2009 until April 2016","Senior Vice President of Drug Development at Incyte from August 2003 to January 2009","Vice President, Biologic Therapies, at Celgene from 2002 to 2003","Various executive positions with DuPont Pharmaceuticals Company from 1997 to 2001","Increasing responsibility in clinical research and regulatory affairs at Novartis AG from 1991 to 1997","Part-time Senior Advisor for BBA from December 2016 to May 2019","Board Certified in Internal Medicine and Gastroenterology"] | ["Audit","Science and Technology","Nominating and Governance","Science and Technology Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| KOD | Director; Board Member | 68 | ["senior advisor of Baker Bros. Advisors LP","Executive Vice President and Chief Drug Development Officer of Incyte Corporation","Senior Vice President of Drug Development at Incyte","Vice President, Biologic Therapies at Celgene Corporation","various executive positions with DuPont Pharmaceuticals","Assistant Professor of Medicine at UCLA School of Medicine"] | ["Nominating and Governance","Nominating and Corporate Governance"] | 2026 |
Biography sourced from the proxy statement filing.
Executive Vice President and Chief Drug Development Officer at Incyte from January 2009 until his retirement in April 2016. Previously served as Senior Vice President of Drug Development at Incyte from August 2003 to January 2009. Vice President, Biologic Therapies, at Celgene from 2002 to 2003. Served in various executive positions with DuPont Pharmaceuticals Company (DuPont), first as Vice President, Regulatory Affairs and Pharmacovigilance, and thereafter as Vice President, Medical and Commercial Strategy, from 1997 to 2001. Served in positions of increasing responsibility in clinical research and regulatory affairs at Novartis AG (Novartis), and its predecessor company Sandoz, from 1991 to 1997. Part-time Senior Advisor for BBA, from December 2016 to May 2019. Board Certified in Internal Medicine and Gastroenterology and served as Assistant Professor of Medicine at the UCLA School of Medicine from 1989 to 1991. Previously served on the board of directors of Constellation Pharmaceuticals, Inc. from April 2020 to July 2021. Dr. Levy received his A.B. in Biology from Brown University and his M.D. from the University of Pennsylvania School of Medicine, and completed his training in Internal Medicine at the Hospital of the University of Pennsylvania and a fellowship in Gastroenterology and Hepatology at UCLA. Other Company Board Service Dr. Levy serves on the board of directors of the following publicly traded companies: ProTara Therapeutics, Inc. since December 2019 Kodiak Sciences, Inc. since May 2018 Kiniksa Pharmaceuticals, Ltd. since March 2019 Qualifications We believe that Dr. Levy is qualified to serve on our Board due to his extensive and diverse experience in the pharmaceutical and biotechnology industries.